## **WHO** approves R21 malaria vaccine for use

EXPRESS NEWS SERVICE PUNE, OCTOBER 2

THE R21/Matrix-M<sup>â„¢</sup> malaria vaccine developed by the University of Oxford and the Serum Institute of India, leveraging Novavax's adjuvant technology, has been recommended for use by the World Health Organization (WHO) after meeting required safety, quality and effectiveness standards.

The Serum Institute of India has already established production capacity for 100 million doses per annum, which will be doubled over the next two years, the statement said.

The vaccine was developed by the Jenner Institute at Oxford University and Serum Institute of India with support from European and Developing Countries Clinical Trials Partnership ('EDCTP'), the Wellcome Trust, and the European Investment Bank ('EIB').